NMDP’s Post

If your clinical trial protocol is at a stage where adjustments are still possible, DAC-A is here to help review and provide feedback that could help optimize the clinical trial protocol for the trial to have an informative outcome. DAC-A's goal is to promote clinical trial informativeness in Africa.

⚡Last Thursday, we held a regular meeting of the Clinical Trials Subcommittee. We discussed with the community the results of the Subcommittee's work for the first half of the year, the status of current projects, and further actions to improve the conditions for conducting clinical trials in Ukraine. 🙌Sincerely grateful to the CTS Board and all representatives of the EBA Clinical Trials Subcommittee member companies for their active participation in the Subcommittee's activities. #clinicaltrials #clinicalresearch #CTS #EBA #ClinicalTrialsSubcommittee

🌍✨ Exciting Times at #CRIntegration: Pioneering Clinical Trials in the SADC Region! At CR Integration, we're thrilled to unveil our comprehensive threefold plan, poised to shape the future of clinical trials across the SADC region. 🚀🌐 Our vision is encapsulated in the video below, where we delve into the dynamic strategies that will revolutionize the clinical research landscape. 📽️💡 Join us in this transformative journey of healthcare excellence in Southern Africa! 🤝🌟 #ClinicalTrials #SADCRegion #HealthcareInnovation #FutureOfHealthcare #ClinicalResearch #GameChangers"

Today is #rarediseaseday and sees the completion day of our #SUPPLYProject Many #raredisease patients depend on plasma medicines and need a stable and adequate supply. The SUPPLY project provides a set of recommendations and guidance (available here: https://lnkd.in/eMzTYJvy ) for the EU, National Governments, blood establishments, competent authorities, medical societies, and other professional stakeholders to meet this need. 👉 Now is the time for policymakers, healthcare providers, and stakeholders to consider the guidance provided and work collaboratively to achieve optimal availability of plasma medicines for patients. 👉 Now is the time to examine the recommendations provided to increase plasma collection in the EU by the public health sector to ensure a sufficient, adequate, and resilient supply of plasma and to contribute to European self-sufficiency. 👉 Now is the time to review the recommendations and guidance provided and implement the measures required to ensure the plasma and PDMP system is robust and resilient now and in the next times of crisis. 👉 Now is the time to act in the interests of patients, donors, and all EU citizens.

Excellent Well done Congratulations Nouzha WiNMI leader,Group Expert of WiN Global EANM_WE,Vp #WiN Global,#WiNMI,#WiN for peace,#WiN YG,#WiN Africa,#WiN IAEA,#WiN France,#WiN Europe,#AMMN ,#SNMMI,#PSNM,#AI,#Nuclear Medicine,#Oncology,#Molecular Imaging,#Myocardial imaging,#ASCO,#EANM,#EANM_WE,#EANM_WE, #WARMTH, #alpha Therapy, #beta Nuclear Medicine therapyVp,#Oncidium,#ESMIT,#SFMN,#UCLA,#EJNMMI,#Americanoncologyinstitute,#Urology,#Prostate cancer,#CEA,#INSTN,#Clinical Nuclear Medicine ,#Endocrinology,#Parathyroid

Step 1: Sponsor approaches Clinical Research Payment Network (CRPN) and joins as a member. Step 2: Sponsor presents trial to CRPN Network. CRPN compares to site network and profiles for compatible site. Step 3: Sponsor selects CRPN site partners to do research. Step 4: Site begins research that day. Its that simple. CRPN creates a much needed bridge of time and financial support between sites and sponsors. No more months of bickering over a budget. And no more toxic communication pathways that go nowhere. ............................................. If you think this is a myth - think again. Pilot studies are testing as we speak, and results demonstrate proof of concept as planned. CRPN rapidly deploys trials, pays sites on time, and ensures full accountability between sites, sponsors, and the industry. Join FREE as a site or affordably as a sponsor. Access CRPN's growing site network for optimal trial performance. And...... Experience the ▲ #crpn

Now on the #ACGME Blog! In a more personal President’s Plenary at #ACGME2024, his last as ACGME President and CEO, Dr. Thomas Nasca discussed many issues facing #GME, all viewed through the lens of trust. #MeaningInMedicine #MedEd https://lnkd.in/e95fCk55

#WODC World Orphan Drug Congress Europe At the question, « are we ready for 2025 to start performing Joint Clinical Assessment ? », we reminded, as key panelists, all the preparatory work done by EUnetHTA - European Network for Health Technology Assessment. There is still a lot to be done, starting by the finalisation of the implementing acts that will notably specify the process of joint clinical assessment. There are many procedures, guidelines, implementing acts that will be published in the upcoming months. This regulation head us to produce for all, high scientific quality reports to facilitate access to innovative products across Europe. Haute Autorité de Santé’s teams are highly committed to give a broader access to innovative health products for all european patients and specifically for those living with a rare disease. Lionel Collet Floriane Pelon Judith Fernandez Camille Thomassin Sophie Kelley Causeret Cédric CARBONNEIL Hubert Galmiche

🎆 Looking back again at the activity of our Federation, as we celebrate this month 10 years since its foundation... Although it is one of our main goals, equal access to treatment is still not achieved across Europe. However, every little step we are able to take forward to make new medicines available to as many patients as possible is a moment of celebration to us. Approved by the European Commission in late 2020, Fintepla (Fenfluramine) is the proof that standing together can really generate a strong impact. Among the initiatives that accelerated its approval was a survey done by Dravet Syndrome European Federation during the summer of that year to show the patients’ perspective on the benefits the new medicine was having. 💊 Fenfluramine clinical trials were conducted in the pediatric population, between 2 and 18 years, but the Federation collected data from patients between 1 and 40 years. So, this initiative contributed to the fact that the drug also got approved for the adult population. The survey included 118 patients in Italy, Spain, Netherlands, France, Belgium, Switzerland, UK, Germany and US. 👉 Do you have a story on how your life with Dravet changed with a new treatment? We would like to hear it and celebrate together with you! #DSEF10 #DravetSyndrome #Fight4DravetPatients

Today, the first meeting of the working group on clinical trials took place. It's reassuring to see that all industry stakeholders are interested in quality changes. Thank you Maryna Slobodnichenko and Ministry of Health experts, Ivan Vyshnyvetskyy with Ukrainian Association for Clinical Research team and Yuriy Lebed and other participants for your support and vision 💥 The main topics discussed were the integration of regulatory documents with European Union directives, improving the business climate, and establishing international communication regarding the operation of the clinical trials industry in Ukraine. #clinicaltrials #cro #gr #clinicalstudy #ukraine #ministryofhealth